The funding round was led by GV, with participation from Iaso Ventures and Virtue. The company aims to empower biopharma companies to accelerate drug pipelines and maximize return on investment, ensuring healthcare innovations reach their clinical development milestones, patient impact and full commercial potential. Prudentia's platform also enables investors in making data-driven decisions for portfolio strategy planning including, capital allocation in drug asset transactions and showcasing the value of assets effectively for dealmaking purposes.

Prudentia Sciences, a technology company, is dedicated to accelerating drug pipelines and maximizing return on investment, envisioning a future where healthcare innovations reach their full potential. Prudentia's platform enables comprehensive due diligence and valuation of drug assets.